Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026427 | 1.00 | TSHR (0.59) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL1172246 | 1.00 | TSHR (0.59) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL27881030 | 0.83 | SMN1; SMN2 (0.48) | TSHRTP53PDCD1CD274NPC1 | |
| SCHEMBL10239104 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL6660758 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL29311500 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA | |
| Benzoic Acid 1-Methylethyl Ester SCHEMBL96918 | 0.83 | PDCD1 (0.78) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL13700339 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL10698829 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL13625602 | 0.83 | TSHR (0.63) | TSHRTP53PDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394970-A | Ester Furimazine derivative, preparation method and application thereof | 山东大学 | 2022-04-26 | — | — | CN | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2014031844-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| EP-2515876-A2 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE | XenoPort, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | claimed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-4960873-A | 3-pyridylisothiazoleazo compounds useful as disperse dyes | BASF AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| CN-118109069-A | Resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108899-A | Curable resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| EP-0109937-A2 | Colour-photographic recording material | CIBA-GEIGY AG (CH) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4113720-A | Disperse azo dye with diaminopyrimidine coupling component | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TSHR 3968/4885TP53 963/4885PDCD1 3495/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | TSHR 4601/4885TP53 296/4885PDCD1 4755/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | TSHR 4809/4885TP53 944/4885PDCD1 2501/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TSHR 3968/4885TP53 963/4885PDCD1 3495/4885 |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | TSHR 3809/4885TP53 2133/4885PDCD1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.